Drug Profile
Research programme: haemophilia therapy - 3B Pharmaceuticals/Takeda
Latest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator Baxalta; Jerini
- Developer 3B Pharmaceuticals; Shire
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haemophilia
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 28 Feb 2018 No recent reports of development identified for preclinical development in Haemophilia in Germany
- 03 Jun 2016 Baxalta has been acquired and merged into Shire